Abstract
Monoclonal gammopathies regardless their malignant or benign characteristics are considered as a risk factor for development of venous thromboembolism (VTE). Incidence of VTE in monoclonal gammopathies of undetermined significance (MGUS) varies among 67 % which is significantly higher rate than in population without MGUS.
Malignant transformation of MGUS and cytostatic treatment furhther increase the risk of VTE. Recently several new drug groups have been introduced into treatment regimens of multiple myeloma.
The group of immunomodulatory drugs (thalidomide, lenalidomide) especially when combined with corticosteroids carries the highest risk of VTE. The incidence of VTE in this combination can be uo to 20 %.
In some studies lenalidomide with corticosteroids reach VTE incidence of 75 %. Pathogenetic mechanism of these events remains poorly understood.
From the reasons mentioned above there is a big effor made to estabilish an effective thromboprophylaxis in patients with MGUS and multiple myeloma.